London +4420 814 42225
Moscow +7495 543 9194
Kiev +38044 599 2950
info@mrcplast.com

Our Clients

Order Informer

 
Home > News >
 

Hubei Biocause Pharmaceutical to invest in propylene production

October 22/2010

(Plastemart) -- Hubei Biocause Pharmaceutical plans to invest 301.96 mln yuan in propylene production, which uses the process of catalytic cracking of C4 olefin.


About 200.02 mln yuan will be earmarked for construction costs and 101.94 mln yuan for working capital. Capacities at the plant will comprise 21,800 tons of propylene, 10,000 tons of propane and 120,000 tons of liquefied natural gas.


mrcplast.com


Tags:No
Category:General News
|
| More

Leave a comment

MRC help

 


 All News   News subscribe